Aprinoia Therapeutics Inc.
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Initiation of a Phase 2 Multicenter Study of 18F-APN-1607, a Novel Diagnostic PET Imaging Tracer for the Characterization of Tau Burden in Alzheimer's Disease 2019-11-21 23:00
APRINOIA Therapeutics Awarded Grant from The Michael J. Fox Foundation for Parkinson's Research 2019-05-23 20:00
APRINOIA Therapeutics Licenses Tau PET Imaging Tracer APN-1607 to Celgene 2019-01-02 08:00
APRINOIA Therapeutics Closes US$11 Million Series B Financing to Advance Its Tau PET Imaging Tracer and Tau Therapeutic Programs for Alzheimer's Disease 2018-01-16 14:54
1